GLP-1 agonist medications work bymimickingthis hormone. In medication terms, anagonistis amanufacturedsubstance that attaches to a cell receptor and causes the same action as the naturally occurring substance. In other words, GLP-1 medications bind to GLP receptors to trigger the effects (or roles...
Daniel Drucker et al.Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation. Cell Metabolism, 2024, doi:10.1016/j.cmet.2023.11.009. Study identifies new concepts for GLP-1 action in the brain https://medicalxpress.com/news/2023-12-concepts-glp...
Daniel Drucker et al. Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation. Cell Metabolism, 2024, doi:10.1016/j.cmet.2023.11.009. Study identifies new concepts for GLP-1 action in the brain https://medicalxpress.com/news/2023-12-concepts-g...
Literature survey has been done by searches in Google, Google Scholar, Science direct and PubMed using the terms “GLP-1R agonist”, “Exenatide”, “Liraglutide”, “Semaglutide”, “Efpeglenatide”, “Exenatide”ER, “Ittca 650(Intarcia)”, “Exenatide LAR”, “Albiglutide”, “Dulaglutide...
Daniel Drucker et al. Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation. Cell Metabolism, 2024, doi:10.1016/j.cmet.2023.11.009. Study identifies new concepts for GLP-1 action in the brain ...
[12] Noyan-Ashraf, M.H., Momen, M.A., Ban, K., Sadi, A.M., Zhou, Y.Q., Riazi, A.M., et al. 2009. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975-983. ...
Daniel Drucker et al.Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation. Cell Metabolism, 2024, doi:10.1016/j.cmet.2023.11.009. Study identifies new concepts for GLP-1 action in the brain ...
[12]Noyan-Ashraf, M.H., Momen, M.A., Ban, K., Sadi, A.M., Zhou, Y.Q., Riazi, A.M., et al. 2009. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardi...
【Key words 】 Diabetes mellitus, type 2; Atherosclerotic cardiovascular disease; Glucagon‑likepeptide‑1 receptor agonist 胰高糖素样肽‐1受体激动剂(GLP‐1RA)通过 的食欲抑制来减少进食量,从而达到降低血糖的作 模拟天然胰高糖素样肽‐1(GLP‐1)激活GLP‐1受 用。GLP‐1RA不仅降糖效果显著,单独使用...
[6] Moon HS, et al. The development of non-peptide glucagon-like peptide-1 receptor agonist ...